Hemogenyx Pharmaceuticals PLC Announces Director/PDMR Shareholding
Hemogenyx Pharmaceuticals announces that Andrew Wright, the Financial Controller and Company Secretary, purchased 1,284,889 ordinary shares at a price of 1.44p each. Post-transaction, Wright holds a total of 4,000,000 shares, representing approximately 0.41% of the company's issued capital. This acquisition signals confidence in the company's future performance, with the transaction value totaling £18,502.40. The purchase occurred on May 27, 2022, on the London Stock Exchange.
- Insider purchase of 1,284,889 shares by Financial Controller indicates confidence in the company's prospects.
- Post-transaction, total holdings of Andrew Wright represent approximately 0.41% of the company.
- None.
LONDON, UK / ACCESSWIRE / May 30, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately 0.41 per cent of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1. | Details of PDMR/person closely associated with them ("PCA") | |
| a) | Name | Andrew Wright |
| 2. | Reason for the notification | |
| a) | Position/status | Financial Controller and Company Secretary |
| b) | Initial notification/ amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Full name of the entity | Hemogenyx Pharmaceuticals plc |
| b) | Legal Entity Identifier code | 2138008L93GYU5GN6179 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of Hemogenyx Pharmaceuticals plc GB00BYX3WZ24 |
| b) | Nature of the transaction | Standalone acquisition of shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) GBP £0.0144 1,284,889 |
| d) | Aggregated information - Aggregated volume - Price | Price(s) Volume(s) GBP £18,502.40 1,284,889 |
| e) | Date of the transaction | 2022-05-27 |
| f) | Place of the transaction | London Stock Exchange XLON |
Enquiries:
Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
Peter Redmond, Director | peter.redmond@hemogenyx.com |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/703196/Hemogenyx-Pharmaceuticals-PLC-Announces-DirectorPDMR-Shareholding
FAQ
What recent share purchase was made by Hemogenyx Pharmaceuticals?
How many shares does Andrew Wright now hold in Hemogenyx Pharmaceuticals?
When did Andrew Wright purchase shares in Hemogenyx Pharmaceuticals?
What percentage of the company does Andrew Wright's shares represent?
What was the total value of the shares purchased by Andrew Wright?
